Related Experiment Video
Updated: Feb 12, 2026
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
69.0K
The IBD and PSC Phenotypes of PSC-IBD
Amanda Ricciuto1, Binita M Kamath2, Anne M Griffiths2
1Division of Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, M5G1X8, Canada. amanda.ricciuto@sickkids.ca.
Current Gastroenterology Reports
|March 30, 2018
Summary
Inflammatory bowel disease (IBD) co-occurring with primary sclerosing cholangitis (PSC) presents a distinct clinical and genetic profile, often featuring subclinical inflammation and an increased risk of colorectal dysplasia. Colectomy may reduce recurrent PSC after liver transplantation.
Area of Science:
- Gastroenterology
- Hepatology
- Immunology
Background:
- Inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) are chronic inflammatory conditions.
- The association between IBD and PSC is complex, influencing disease progression and treatment outcomes.
- Understanding the interplay between these conditions is crucial for managing affected patients.
Purpose of the Study:
- To review the characteristics of IBD and PSC when they co-occur.
- To examine the reciprocal influences of IBD and PSC on disease evolution.
- To analyze these associations in both adult and pediatric populations.
Main Methods:
- Literature review of studies investigating IBD and PSC co-occurrence.
- Analysis of clinical, genetic, and epidemiological data.
- Synthesis of findings on disease phenotype, risk factors, and treatment implications.
Main Results:
- IBD with PSC is genetically and clinically distinct from IBD alone, often showing pancolitis and increased colorectal dysplasia risk.
- Patients with colitis and PSC exhibit increased risk of active endoscopic/histologic disease, even without symptoms.
- PSC with Crohn's disease appears less severe than with ulcerative colitis; colectomy may decrease recurrent PSC post-liver transplant.
Conclusions:
- IBD associated with PSC has a unique phenotype, including significant subclinical inflammation.
- Colectomy's role in preventing recurrent PSC post-transplantation warrants further investigation.
- More research is needed on the gut-liver axis and the impact of IBD control on PSC progression.
Keywords:
ColectomyInflammatory bowel disease (IBD)Liver transplantationPSC-IBDPhenotypePrimary sclerosing cholangitis (PSC)More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
537
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
537
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
523
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
523
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
558
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
558
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
584
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
584
02:27Background and Environment Affect Phenotype
7.7K
Although the genetic makeup of an organism plays a major role in determining the phenotype, there are also several environmental factors, such as temperature, oxygen availability, presence of mutagens, that can alter an organism’s phenotype.
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
7.7K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
3
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
3